Ylikorkala O, Kaila J, Viinikka L
Br Med J (Clin Res Ed). 1981 Oct 31;283(6300):1148-50. doi: 10.1136/bmj.283.6300.1148.
Concentrations of the stable antiaggregatory prostacyclin metabolite 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) and of the proaggregatory thromboxane A2 metabolite thromboxane B2 were measured by radioimmunoassay in plasma from 53 diabetics. In 33 of these patients the ability of platelets to produce thromboxane B2 during spontaneous clotting was also studied. Plasma 6-keto-PGF1 alpha concentrations were higher (p less than 0.05) in the diabetics (mean 107.7 +/- SE 7.6 ng/l) than in non-diabetic controls matched for age and sex (87.5 +/- 4.7 ng/l), and diabetics with microangiography (n = 28) and higher (p less than 0.01) concentrations (124.3 +/- 10.8 ng/l) than those without microangiography (n = 25; 89.2 +/- 9.3 ng/l). Plasma thromboxane B2 concentrations were also higher (p less than 0.01) in the diabetics (mean 218.5 +/- SE 25.3 ng/l) than in the controls (127.7 +/- 9.8 ng/l), but this increase was not related to microangiography. The ability of platelets to generate thromboxane B2 did not differ between the diabetics (181.4 +/- 16.4 microgram/l) and controls (195.8 +/- 11.8 microgram/l). Platelets of diabetics with microangiopathy or taking oral hypoglycaemic agents (n = 19), however, produced decreased amounts of thromboxane B2 during clotting. Plasma concentrations of 6-keto-PGF1 alpha and thromboxane B2 were not related to concentrations of glucose, haemoglobin A1, high-density lipoprotein cholesterol, cholesterol, triglycerides, magnesium, or creatinine. These results suggest that in diabetics with microangiopathy a balance between prostacyclin and thromboxane A2 is shifted to dominance by prostacyclin.
采用放射免疫分析法测定了53例糖尿病患者血浆中稳定的抗聚集性前列腺素代谢产物6-酮-前列腺素F1α（6-keto-PGF1α）和促聚集性血栓素A2代谢产物血栓素B2的浓度。其中33例患者还研究了血小板在自发凝血过程中产生血栓素B2的能力。糖尿病患者（平均107.7±标准误7.6 ng/l）血浆6-酮-PGF1α浓度高于年龄和性别匹配的非糖尿病对照组（87.5±4.7 ng/l，p<0.05），有微血管病变的糖尿病患者（n = 28）血浆6-酮-PGF1α浓度更高（124.3±10.8 ng/l，p<0.01），高于无微血管病变的患者（n = 25；89.2±9.3 ng/l）。糖尿病患者血浆血栓素B2浓度（平均218.5±标准误25.3 ng/l）也高于对照组（127.7±9.8 ng/l，p<0.01），但这种升高与微血管病变无关。糖尿病患者（181.4±16.4微克/升）和对照组（195.8±11.8微克/升）血小板产生血栓素B2的能力无差异。然而，有微血管病变或服用口服降糖药的糖尿病患者（n = 19）血小板在凝血过程中产生的血栓素B2量减少。血浆6-酮-PGF1α和血栓素B2浓度与血糖、糖化血红蛋白、高密度脂蛋白胆固醇、胆固醇、甘油三酯、镁或肌酐浓度无关。这些结果表明，在有微血管病变的糖尿病患者中，前列腺素和血栓素A2之间的平衡向前列腺素占优势方向转变。
